Replimune (NASDAQ: REPL) CEO receives new stock options and RSUs
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Replimune Group, Inc. disclosed that Chief Executive Officer Sushil Patel received new equity awards as part of his compensation. He was granted an employee stock option for 376,860 shares of common stock at an exercise price of $7.61 per share, expiring on April 1, 2036. According to the vesting schedule, 25% of the option vests on April 1, 2027, with the remainder vesting in 36 approximately equal monthly installments. Patel also received 251,240 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest 25% on May 15, 2027, with the balance vesting in three approximately equal annual installments through May 15, 2030, contingent on continued service. Following these awards, he directly owns 784,816 shares of common stock. These are compensation-related grants rather than open-market purchases.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Patel Sushil
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 376,860 | $0.00 | -- |
| Grant/Award | Common Stock | 251,240 | $0.00 | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 376,860 shares (Direct);
Common Stock — 784,816 shares (Direct)
Footnotes (1)
- Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer. 25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.
Key Figures
Stock options granted: 376,860 options
Option exercise price: $7.61 per share
Option expiration: April 1, 2036
+3 more
6 metrics
Stock options granted
376,860 options
Employee stock option grant on April 1, 2026
Option exercise price
$7.61 per share
Exercise price for 376,860 options
Option expiration
April 1, 2036
Expiration date of granted options
RSUs granted
251,240 RSUs
Restricted stock units granted on April 1, 2026
RSU initial vesting
25% on May 15, 2027
First vesting date for RSU grant
Common shares after grant
784,816 shares
Direct common stock holdings after April 1, 2026 awards
Key Terms
Employee Stock Option, restricted stock units ("RSUs"), vesting, contingent right to receive, +1 more
5 terms
Employee Stock Option financial
"Represents an Employee Stock Option (right to buy) with an exercise price of $7.61"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
restricted stock units ("RSUs") financial
"Represents shares issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vesting financial
"25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
contingent right to receive financial
"Each RSU represents a contingent right to receive one share of the Issuer's common stock"
exercise price financial
"25% of the shares underlying this stock option vest on April 1, 2027, with an exercise price of $7.61"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What equity awards did Replimune (REPL) CEO Sushil Patel receive?
Sushil Patel received an option to buy 376,860 Replimune shares at $7.61 and 251,240 RSUs. Both awards vest over several years, tying much of his compensation to the company’s long-term stock performance and his continued service.
What is the vesting schedule for Sushil Patel’s new Replimune (REPL) stock options?
The stock options vest 25% on April 1, 2027, with the remaining shares vesting in 36 approximately equal monthly installments. This structure encourages long-term alignment, as full vesting occurs gradually after the initial three-year cliff date.
How do Sushil Patel’s Replimune (REPL) RSUs vest over time?
The 251,240 RSUs vest 25% on May 15, 2027, then in three approximately equal annual installments through May 15, 2030. Each RSU converts into one Replimune common share when vested, conditioned on Patel’s continuous service with the company.
What is the exercise price and expiration date of the new Replimune (REPL) stock options?
The new employee stock options have an exercise price of $7.61 per share and expire on April 1, 2036. Patel can only benefit if Replimune’s market price exceeds this level after vesting and before the options expire.